Development And Sale Of Alzheimer’s Drug, Aducanumab, Ceased
The pharmaceutical company, Biogen, announced this week that it will stop developing and marketing the Alzheimer’s drug aducanumab (commercially known as Aduhelm). Aducanumab is designed…
Read more...